Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C12H21N3O8
CAS Number:
Molecular Weight:
335.31
NACRES:
NA.25
PubChem Substance ID:
UNSPSC Code:
12352201
MDL number:
InChI
1S/C12H21N3O8/c1-4(17)14-8-10(20)9(19)6(3-16)23-11(8)15-7(18)2-5(13)12(21)22/h5-6,8-11,16,19-20H,2-3,13H2,1H3,(H,14,17)(H,15,18)(H,21,22)
SMILES string
CC(=O)NC1C(O)C(O)C(CO)OC1NC(=O)CC(N)C(O)=O
InChI key
YTTRPBWEMMPYSW-UHFFFAOYSA-N
assay
≥98%
form
powder
optical activity
[α]/D 22 to 26 °, c = 1% (w/v) in water
technique(s)
thin layer chromatography (TLC): suitable
storage temp.
−20°C
Application
n-acetylglucosaminylasparagine [2-Acetamido-1-N-(β-L-aspartyl)-2-deoxy-β-D-glucopyranosylamine] may be useful in studies on Aspartylglycosaminuria.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
U Dunder et al.
FEBS letters, 499(1-2), 77-81 (2001-06-22)
Aspartylglycosaminuria (AGU), a severe lysosomal storage disease, is caused by the deficiency of the lysosomal enzyme, glycosylasparaginase (GA), and accumulation of aspartylglucosamine (GlcNAc-Asn) in tissues. Here we show that human leukocyte glycosylasparaginase can correct the metabolic defect in Epstein-Barr virus
M Arvio et al.
Acta neurologica Scandinavica, 112(5), 335-337 (2005-10-13)
To show that the head may shrink in adult patients with aspartylglucosaminuria (AGU), a neurodegenerative disease. The head circumference (HC) of 40 adult patients (age at baseline 15 to 47) was measured twice with an interval of 10 years. Of
Niki Lindblom et al.
Journal of inherited metabolic disease, 29(5), 637-646 (2006-09-01)
Sleep disturbances are common in many progressive metabolic encephalopathies. The possible presence of disturbed sleep-wake behaviour in the lysosomal storage disorder aspartylglucosaminuria, has not been previously studied, however. The sleep-wake behaviour of 81 patients with aspartylglucosaminuria (AGU, age 3-55 years
J M Risley et al.
Journal of enzyme inhibition, 16(3), 269-274 (2001-11-08)
Glycosylasparaginase catalyzes the hydrolysis of the N-glycosylic bond between asparagine and N-acetylglucosamine in the catabolism of N-linked glycoproteins. Previously only three competitive inhibitors, one noncompetitive inhibitor, and one irreversible inhibitor of glycosylasparaginase activity had been reported. Using human glycosylasparaginase from
Ulla Dunder et al.
Journal of inherited metabolic disease, 33(5), 611-617 (2010-07-08)
Aspartylglycosaminuria (AGU) is a lysosomal storage disease caused by deficient activity of glycosylasparaginase (AGA), and characterized by motor and mental retardation. Enzyme replacement therapy (ERT) in adult AGU mice with AGA removes the accumulating substance aspartylglucosamine from and reverses pathology
Articles
N-linked glycosylation, modification, and degradation
N-连接聚糖、修饰和降解
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service